The FDA has approved Sumavel DosePro (sumatriptan injection, from Zogenix and Astellas), a selective 5-HT1B/1D receptor agonist in a needle-free delivery system, for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes. The DosePro technology is an easy-to-use, pre-filled drug delivery system designed to enable self-administration of single doses of liquid drug formulations, subcutaneously, without a needle.

Sumavel DosePro is expected to be available in January 2010 as a 6mg/0.5mL single-use, disposable injection.

For more information call (866) ZOGENIX or visit